Idea GmbH
This article was originally published in Start Up
Executive Summary
Drug Delivery, Large Molecule. Idea GMBH uses composites of pharmaceutically-accepted ingredients to deliver drugs across the skin barrier. {Transfersomes} take advantage of the natural moisture gradient across the skin to temporarily open up channels between adjoining cells. The technology may deliver macromolecules, such as insulin, across the skin barrier.
You may also be interested in...
Focus on Germany
Germany is addressing its problems of lack of management and capital for start-up biotechs.
Making The Most Of ACOs: How Biopharma Is Adapting To New Customer Segment
ACOs have been one of the most hyped innovations in the US health care sector this decade. The buzz may be overdone, but ACOs are now established as a different—and confusing—new customer segment for pharma. How is industry adjusting?
Building Long-Term Value Into Near-Term Commercial Strategy
Pharma companies are building long-term value propositions that should appeal to Accountable Care Organizations into some go-to-market strategies for new drugs and to repositioning efforts of already marketed drugs that have hit snags. The rationale might seem straightforward—for example, more convenient dosing that improves compliance and cuts down hospitalization rates--but the nuances can be complex. Moreover, even when their products appear to have compelling cases for value, companies have not by and large made ACOs a distinct target for their commercial operations.